Literature DB >> 17850170

Hashimoto's encephalopathy : epidemiology, pathogenesis and management.

Ramon Mocellin1, Mark Walterfang, Dennis Velakoulis.   

Abstract

Hashimoto's encephalopathy is a term used to describe an encephalopathy of presumed autoimmune origin characterised by high titres of antithyroid peroxidase antibodies. In a similar fashion to autoimmune thyroid disease, Hashimoto's encephalopathy is more common in women than in men. It has been reported in paediatric, adult and elderly populations throughout the world. The clinical presentation may involve a relapsing and remitting course and include seizures, stroke-like episodes, cognitive decline, neuropsychiatric symptoms and myoclonus. Thyroid function is usually clinically and biochemically normal.Hashimoto's encephalopathy appears to be a rare disorder, but, as it is responsive to treatment with corticosteroids, it must be considered in cases of 'investigation negative encephalopathies'. Diagnosis is made in the first instance by excluding other toxic, metabolic and infectious causes of encephalopathy with neuroimaging and CSF examination. Neuroimaging findings are often not helpful in clarifying the diagnosis. Common differential diagnoses when these conditions are excluded are Creutzfeldt-Jakob disease, rapidly progressive dementias, and paraneoplastic and nonparaneoplastic limbic encephalitis. In the context of the typical clinical picture, high titres of antithyroid antibodies, in particular antithyroid peroxidase antibodies, are diagnostic. These antibodies, however, can be detected in elevated titres in the healthy general population. Treatment with corticosteroids is almost always successful, although relapse may occur if this treatment is ceased abruptly. Other forms of immunomodulation, such as intravenous immune-globulin and plasma exchange, may also be effective. Despite the link to autoimmune thyroid disease, the aetiology of Hashimoto's encephalopathy is unknown. It is likely that antithyroid antibodies are not pathogenic, but titres can be a marker of treatment response. Pathological findings can suggest an inflammatory process, but features of a severe vasculitis are often absent. The links between the clinical pictures, thyroid disease, auto-antibody pattern and brain pathology await further clarification through research. It may be that Hashimoto's encephalopathy will be subsumed into a group of nonvasculitic autoimmune inflammatory meningoencephalopathies. This group may include disorders such as limbic encephalitis associated with voltage-gated potassium channel antibodies. Some authors have suggested abandoning any link to Hashimoto and renaming the condition 'steroid responsive encephalopathy associated with autoimmune thyroiditis' to better reflect current, if limited, understanding of this condition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17850170     DOI: 10.2165/00023210-200721100-00002

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  91 in total

1.  Brain biopsy in primary angiitis of the central nervous system.

Authors:  A Alrawi; J D Trobe; M Blaivas; D C Musch
Journal:  Neurology       Date:  1999-09-11       Impact factor: 9.910

2.  Amnesic syndrome with bilateral mesial temporal lobe involvement in Hashimoto's encephalopathy.

Authors:  D J McCabe; T Burke; S Connolly; M Hutchinson
Journal:  Neurology       Date:  2000-02-08       Impact factor: 9.910

3.  Febrile Hashimoto's encephalopathy.

Authors:  P Papathanasopoulos; K Mallioris; P Karanasios; D Dimopoulos; T Papapetropoulos
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-06       Impact factor: 10.154

4.  Neuropathology of Hashimoto's encephalopathy.

Authors:  W Paulus; K W Nolte
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-07       Impact factor: 10.154

5.  Hashimoto's disease and encephalopathy.

Authors:  L Brain; E H Jellinek; K Ball
Journal:  Lancet       Date:  1966-09-03       Impact factor: 79.321

Review 6.  The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: a literature investigation.

Authors:  F G I Jennekens; L Kater
Journal:  Rheumatology (Oxford)       Date:  2002-06       Impact factor: 7.580

7.  Hashimoto's encephalopathy: documentation of mesial temporal seizure origin by ictal EEG.

Authors:  A Arain; B Abou-Khalil; H Moses
Journal:  Seizure       Date:  2001-09       Impact factor: 3.184

8.  Choreic syndrome due to Hashimoto's encephalopathy.

Authors:  Gregory Taurin; Véronique Golfier; Jean-François Pinel; Véronique Deburghgraeve; Jean-Yves Poirier; Gilles Edan; Marc Vérin
Journal:  Mov Disord       Date:  2002-09       Impact factor: 10.338

Review 9.  Brain biopsy in dementia.

Authors:  J D Warren; J M Schott; N C Fox; M Thom; T Revesz; J L Holton; F Scaravilli; D G T Thomas; G T Plant; P Rudge; M N Rossor
Journal:  Brain       Date:  2005-05-18       Impact factor: 13.501

Review 10.  Lymphocytic hypophysitis: disease spectrum and approach to diagnosis and therapy.

Authors:  Juan-Andres Rivera
Journal:  Pituitary       Date:  2006       Impact factor: 3.599

View more
  59 in total

1.  Hashimoto's encephalopathy: neuropsychological findings.

Authors:  I Mazzù; S Mosti; C Caltagirone; G A Carlesimo
Journal:  Neurol Sci       Date:  2011-10-13       Impact factor: 3.307

2.  Whipple's disease masquerades as dementia with Lewy bodies.

Authors:  Kyle Hurth; Rawan Tarawneh; Nupur Ghoshal; Tammie L S Benzinger; David B Clifford; Michael Geschwind; John C Morris; James E Galvin; Robert E Schmidt; Nigel J Cairns
Journal:  Alzheimer Dis Assoc Disord       Date:  2015 Jan-Mar       Impact factor: 2.703

3.  Focal neurological presentation in Hashimoto's encephalopathy mimicking a vascular occlusion of the middle cerebral artery.

Authors:  Ahmad Alazzeh; Sarah Jaroudi; Matthew Gooch; Alan N Peiris
Journal:  BMJ Case Rep       Date:  2017-07-14

4.  Functional neuroimaging in Hashimoto's encephalitis: a physiopathological imaging?

Authors:  Jordi Fuertes; Amparo García-Burillo; Joan Castell-Conesa; Isabel Roca
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-21       Impact factor: 9.236

5.  A follow-up ¹⁸F-FDG brain PET study in a case of Hashimoto's encephalopathy causing drug-resistant status epilepticus treated with plasmapheresis.

Authors:  Elisa Pari; Fabrizio Rinaldi; Enrico Premi; Maria Codella; Renata Rao; Barbara Paghera; Maria Beatrice Panarotto; Giovanni De Maria; Alessandro Padovani
Journal:  J Neurol       Date:  2014-01-05       Impact factor: 4.849

Review 6.  [Antibody-associated diseases of the gray matter of the CNS: diagnosis and treatment].

Authors:  C G Bien
Journal:  Nervenarzt       Date:  2011-08       Impact factor: 1.214

7.  Unusual presentations of Hashimoto's encephalopathy: trigeminal neuralgiaform headache, skew deviation, hypomania.

Authors:  Yesim Yetimalar Beckmann; Dilek Top; Tamer Yiğit
Journal:  Endocrine       Date:  2011-12       Impact factor: 3.633

8.  Steroid-responsive encephalopathy: an under recognised aspect of Hashimoto's thyroiditis.

Authors:  Tanawan Riangwiwat; Jutarat Sangtian; Chutintorn Sriphrapradang
Journal:  BMJ Case Rep       Date:  2015-03-12

Review 9.  Immunomodulatory therapies in neurologic critical care.

Authors:  Logan M McDaneld; Jeremy D Fields; Dennis N Bourdette; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2009-09-23       Impact factor: 3.210

10.  Persistent organic pollutants and anti-thyroid peroxidase levels in Akwesasne Mohawk young adults.

Authors:  Lawrence M Schell; Mia V Gallo; Julia Ravenscroft; Anthony P DeCaprio
Journal:  Environ Res       Date:  2008-11-07       Impact factor: 6.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.